Personalised Medicine: Transforming Pharmaceutical Manufacturing for a New Era of Patient Care

Imagine a world where every patient receives the right treatment, at the right dose, at the right time—no more trial-and-error prescribing, fewer side effects, and better outcomes. This is the promise of personalised medicine, and it’s rapidly becoming a reality. For pharmaceutical manufacturers, this shift is both a challenge and an unprecedented opportunity to innovate, differentiate, and deliver greater value to patients and healthcare systems alike.

What is Personalised Medicine?

Personalised medicine (also known as precision medicine) is an approach to healthcare that tailors medical treatment to the individual characteristics of each patient. This includes their genetic makeup, environment, and lifestyle. Instead of the traditional ‘one-size-fits-all’ model, personalised medicine uses advanced diagnostics, genomics, and data analytics to guide prevention, diagnosis, and therapy selection.

Key concepts include:

• Genomics: Analysing a patient’s DNA to predict disease risk and drug response.
• Biomarkers: Identifying molecular indicators that guide therapy choices.
• Pharmacogenomics: Understanding how genetic differences affect drug metabolism and efficacy.
• Companion diagnostics: Tests that match patients to the most effective treatments.

Real-World Examples: Cancer and Cardiovascular Care

Cancer Care: Targeted Therapies and Immunotherapy

Cancer treatment has been at the forefront of personalised medicine. Traditional chemotherapy attacks all rapidly dividing cells, often causing significant side effects. In contrast, targeted therapies and immunotherapies are designed to attack cancer cells with specific genetic mutations or molecular markers.

• HER2-positive breast cancer: Trastuzumab (Herceptin) targets the HER2 protein, overexpressed in some breast cancers.
• Non-small cell lung cancer (NSCLC): EGFR inhibitors (like gefitinib) are prescribed only to patients with specific EGFR mutations.
• Immunotherapy: Drugs like pembrolizumab (Keytruda) are used in cancers with high PD-L1 expression.

Cardiovascular Care: Pharmacogenomics and Risk Stratification

Personalised medicine is also making strides in cardiovascular disease (CVD), the world’s leading cause of death. Here, genetic testing and biomarker analysis are used to predict risk, guide therapy, and prevent adverse drug reactions.

• Clopidogrel (Plavix) and CYP2C19: Genetic variants can reduce drug effectiveness.
• Familial hypercholesterolaemia (FH): Genetic screening identifies individuals at high risk for early heart disease.
• Statin therapy: Genetic markers can predict which patients are more likely to experience side effects.

Impact on Pharmaceutical Manufacturing

The advent of personalised medicine is reshaping pharmaceutical manufacturing, demanding a shift from traditional mass production to highly flexible, patient-centric operations.

Historically, manufacturers have optimised processes for large-scale, standardised products—so-called ‘blockbuster’ drugs—aimed at the broadest possible patient populations. However, the rise of targeted therapies, cell and gene treatments, and bespoke formulations necessitates a move towards smaller batch sizes, greater product variability, and more agile manufacturing environments.

Manufacturing Operations

Production teams must adapt facilities and workflows to accommodate frequent changeovers and variable batch sizes. Technologies such as modular manufacturing, single-use systems, and continuous processing are increasingly vital, enabling rapid reconfiguration and minimising cross-contamination risks. These approaches also support the efficient production of multiple personalised products in parallel, which is essential as the industry moves towards ‘batches of one’ for truly individualised therapies.

Quality Assurance and Control

Quality teams face heightened complexity in validating processes and ensuring compliance for customised products. Each batch may have unique specifications, requiring robust digital quality management systems and real-time monitoring. Advanced analytics and automation are critical for maintaining consistency, traceability, and regulatory compliance, especially as product portfolios diversify and manufacturing cycles shorten.

Supply Chain and Logistics

Personalised medicine introduces new challenges for supply chain professionals. Just-in-time delivery of raw materials and components becomes essential, particularly for biologics and cell therapies that require stringent cold-chain management. Supply chains must be resilient and responsive, leveraging predictive analytics to anticipate demand fluctuations and collaborating closely with logistics partners to ensure timely delivery and product integrity.

Regulatory Affairs

Regulatory teams must navigate evolving frameworks, as well as complex data privacy requirements. Agencies such as the FDA and EMA are piloting regulatory pathways, but manufacturers must remain vigilant in tracking changes and ensuring compliance across global markets.

Personalised medicine introduces significant regulatory complexities for pharmaceutical manufacturers. These challenges span clinical evidence requirements, manufacturing standards, global harmonisation, and co-development of companion diagnostics.

Small Patient Populations & Clinical Evidence

Traditional regulatory pathways rely on large-scale randomised controlled trials, which are often impractical for ultra-rare or bespoke therapies. Regulators such as the FDA are piloting adaptive frameworks that accept mechanistic evidence and smaller sample sizes, but these approaches raise concerns about long-term safety and durability. Manufacturers must plan for post-market surveillance and real-world evidence collection to maintain compliance.

Manufacturing Standards for ATMPs

\Advanced therapy medicinal products (ATMPs), including cell and gene therapies, present unique production challenges such as short shelf-life, batch variability, and contamination risks. Current GMP frameworks were designed for large-scale production and may not fully address these complexities. EU’s hospital exemption (Regulation 1394/2007) allows non-routine in-hospital manufacturing but lacks harmonised quality standards, complicating broader clinical adoption. Manufacturers must implement robust quality systems and engage early with regulators to align on expectations for facility design and process validation.

Divergent International Frameworks

Global regulatory divergence adds complexity for companies operating across multiple jurisdictions. While the FDA supports adaptive approval pathways, the EMA relies on centralised authorisation and hospital exemptions for ATMPs. Harmonisation efforts are ongoing, but manufacturers must maintain agile regulatory strategies and ensure compliance with varying regional requirements.

Companion Diagnostics Co-Development

Personalised therapies often require companion diagnostics (CDx) for patient selection, necessitating simultaneous approval of drug and diagnostic. Regulatory frameworks for analytical and clinical validation are still evolving, creating cost and timeline pressures. Manufacturers should adopt integrated development plans and collaborate closely with diagnostic partners to streamline submissions.

Quality Control & Comparability

Batch-to-batch variability is a major concern for personalised products. Regulators demand stringent comparability data and may require advanced analytics or real-time release testing, but acceptable standards are still being defined. Manufacturers must invest in digital quality systems and automation to meet these expectations while maintaining efficiency.

Regulatory Capacity & Collaboration

Regulatory agencies face capacity constraints in evaluating emerging modalities. Early engagement and transparent communication are critical for aligning expectations. Industry consortia and public-private partnerships can help shape future guidelines and accelerate harmonisation efforts.

Practical Implications for Manufacturers

To navigate these challenges:

• Early and iterative engagement with regulators is essential to align trial design, manufacturing quality and release criteria.
• Investment is required in flexible platforms and digital quality systems to support adaptive regulatory frameworks.
• Cross-functional teams (CMC, RA, QA, diagnostics) must collaborate from early development stages to align regulatory and manufacturing strategies.

Digital Transformation and Cross-Functional Collaboration

Digital technologies underpin the transition to personalised manufacturing. Integration of patient data, diagnostic results, and manufacturing execution systems enables seamless coordination across departments. Industry 4.0 solutions—including IoT sensors, AI-driven predictive maintenance, and blockchain for supply chain transparency—offer significant opportunities to enhance efficiency, compliance, and patient safety. Success in this new era will depend on fostering cross-functional collaboration, investing in workforce training, and embracing innovation at every level of the organisation.
 
Personalised medicine is not merely a scientific evolution; it is a call to reimagine manufacturing strategies, quality systems, and operational models. Pharmaceutical professionals must work collaboratively across disciplines to deliver safe, effective, and truly individualised therapies, positioning their organisations for long-term success in a rapidly changing industry.

How Individuals Can Use DNA Sequencing and AI for Personalised Care

One aspect of personalised medicine is already within our grasp as individuals. Commercial DNA sequencing services, such as 23andMe or AncestryDNA, allow individuals to access their genetic data. Combined with AI-driven platforms, these insights can help predict drug metabolism, nutrient pathways, and disease risk. For example, pharmacogenomic reports can indicate whether a person metabolises certain medications quickly or slowly, guiding safer prescriptions. Nutrigenomics can suggest dietary adjustments based on genetic predispositions, supporting preventive health strategies.

MTHFR mutations

Methylation mutations are extremely common in the human population – it is though that 30-40% of us have one or more such mutations, impacting our ability to metabolise and utilise specific B vitamins. Those with homozygous mutations (around 10%) have a very significantly reduced metabolic capacity.

The consequences of a lifelong diet without awareness of the negative impact of undermethylation of B12 and ingestion of folic acid (a nutrient commonly added to wheat-based foodstuffs under government mandate) can be catastrophic. B12 (cobalamin) is essential throughout the body, being associated with:

• Red blood cell formation
• Myelin sheath production (nerve insulation)
• Energy via fatty acid and amino acid metabolism

Subsequently, B12 deficiency can run a gamut of symptoms and pathological consequences including anaemia, heart failure, neuropathy and myelopathy, infertility, neuropsychiatric symptoms, movement disorders and many, many more.

Identifying appropriate dietary changes and ideal supplementation regimens can be tricky as many genes are implicated in the methylation pathway meaning that there is no “one size fits all” solution. It is a perfect example of the need for individualised medical treatment.

An example

• Scenario: Homozygous mutation of C677T
• Result: Impaired folic acid conversion can result in approximately 10-20% of normal Methylenetetrahydrofolate Reductase (MTHFR) enzyme activity
• Physiological impact: Elevated homocysteine levels
• Pathological consequence: Increased cardiovascular risk, neural tube defects
• Clinical management: Clinically supervised supplementation with vitamins in an activated form to address the patient’s full methylation profile (e.g. folate or L-methylfolate)

Drug metabolism

Genetic variants in drug-metabolising enzymes can influence how efficiently an individual can activate or clear certain medications. Assessing pharmacogenetic Single Nucleotide Polymorphisms (SNPs) from a genome to determine specific genotypes provides knowledge about the drug responses of individual patients.

Existing genetic research about SNPs allows medics to determine in advance how a patient might respond to a proposed treatment – reducing side effects and increasing efficacy so that a patient can be treated more quickly and more effectively.

An example

• Scenario: Heterozygous mutation of TPMT*C (thiopurine methyltransferase)
• Result: Moderate reduction in ability to inactivate thiopurine drugs
• Physiological impact: Moderate risk of toxicity on standard doses of some immunosuppressants including azathiopurine or 6-mercaptopurine
• Pathological consequence: Toxicity can result in myelosuppression (reduced bone marrow function), hepatotoxicity (potential liver damage), pancreatitis (inflammation impacting digestive enzyme and insulin)
• Clinical management: ~30–50% drug dose reduction and close monitoring of blood counts is recommended for TPMT intermediate metabolisers

Note: Having such knowledge about their own genomics allows patients to better advocate for their specific needs, not the needs of the general population; it is not an alternative to seeking appropriate medical care. Always consult with a medical professional when embarking on a supplementation regimen and share your pharmacogenetic results with your doctor so that they can select the best pharmaceutical regimen for you.

How PharmOut Can Help

At PharmOut, we specialise in delivering comprehensive consulting services tailored to the pharmaceutical industry. Our team can help you navigate the transition to personalised medicine manufacturing, implement advanced quality systems, and prepare for regulatory submissions. Explore our GMP training courses at onlinegmptraining.com for practical insights, or contact us via the website or via email for assistance.

Frequently Asked Questions (FAQ)